On September 3, 2025 Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL siRNA gene silencing technology to eliminate cancer, reported that Phio Pharmaceuticals is a presenting company at the H.C. Wainwright 27th Annual Global Investment Conference to be held September 8 – 10, 2025 (Press release, Phio Pharmaceuticals, SEP 3, 2025, View Source [SID1234655732]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Robert Bitterman, President and CEO of Phio Pharmaceuticals will deliver an update on its on-going Phase 1b clinical trial for skin cancer. He will also be discussing strategy and anticipated next steps in the PH-762 development program upon completion of the treatment phase of the study.

· Presentation Details: September 10, 2025 at 1:30-2 PM EST

· Location: 27th Annual H.C. Wainwright Global Investment Conference, Lotte New York Plaza Hotel, New York City, NY

Mr. Bitterman will also be available for one-on-one investor meetings throughout the conference September 8 – 10, 2025. Investors interested in scheduling a meeting with the Phio Pharmaceuticals management team should contact their H.C. Wainwright representative or email [email protected].